Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2006 | Original article

IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies

Authors: Ralph Buchert, Georg Berding, Florian Wilke, Brigitte Martin, Daniel von Borczyskowski, Janos Mester, Winfried Brenner, Malte Clausen

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2006

Abstract

Purpose

Visual reading of [¹²³I]IBZM SPECT scans depends on the experience of the interpreter. Therefore, semi-quantification of striatal IBZM uptake is commonly considered mandatory. However, semi-quantification is time consuming and prone to error, particularly if the volumes of interest (VOIs) are positioned manually. Therefore, the present paper proposes a new software tool (“IBZM tool”) for fully automated and standardised processing, evaluation and documentation of [¹²³I]IBZM SPECT scans.

Methods

The IBZM tool is an easy-to-use SPM toolbox. It includes automated procedures for realignment and summation of multiple frames (motion correction), stereotactic normalisation, scaling, VOI analysis of striatum-to-reference ratio R, classification of R and standardised display. In order to evaluate the tool, which was developed at the University of Hamburg, the tool was transferred to the University of Hannover. There it was applied to 27 well-documented subjects: eight patients with multi-system atrophy (MSA), 12 patients with Parkinson’s disease (PD) and seven controls. The IBZM tool was compared with manual VOI analysis.

Results

The sensitivity and specificity of the IBZM tool for the differentiation of the MSA subjects from the controls were 100% and 86%, respectively. The IBZM tool provided improved statistical power compared with manual VOI analysis.

Conclusion

The IBZM tool is an expert system for the detection of reduced striatal D₂ availability on [¹²³I]IBZM SPECT scans. The standardised documentation supports visual and semi-quantitative evaluation, and it is useful for presenting the findings to the referring physician. The IBZM tool has the potential for widespread use, since it appears to be fairly independent of the performance characteristics of the particular SPECT system used. The tool is available free of charge.

Brucke T, Tsai YF, McLellan C, Singhanyom W, Kung HF, Cohen RM, et al. In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([¹²⁵I]-IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT. Life Sci 1988;42:2097–2104CrossRefPubMed

Costa DC, Verhoeff NP, Cullum ID, Ell PJ, Syed GM, Barrett J, et al. In vivo characterisation of 3-iodo-6-methoxybenzamide¹²³I in humans. Eur J Nucl Med 1990;16:813–816CrossRefPubMed

Kung HF, Alavi A, Chang W, Kung MP, Keyes JW Jr, Velchik MG et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990;31:573–579PubMed

Tatsch K, Schwarz J, Oertel WH, Kirsch CM. SPECT imaging of dopamine D2 receptors with¹²³I-IBZM: initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease. Nucl Med Commun 1991;12:699–707PubMedCrossRef

Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, et al.¹²³I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992;42:556–561PubMed

van Royen E, Verhoeff NF, Speelman JD, Wolters EC, Kuiper MA, Janssen AG. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by¹²³I-IBZM single photon emission computed tomography. Arch Neurol 1993;50:513–516PubMed

Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, et al. Combined¹²³I-FP-CIT and¹²³I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005;112:677–692CrossRefPubMed

Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199–202CrossRefPubMed

Brucke T, Wober C, Podreka I, Wober-Bingol C, Asenbaum S, Aull S, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab 1995;15:513–518PubMed

10.

Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with [¹²³I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 2002;162:42–49CrossRef

11.

la Fougere C, Meisenzahl E, Schmitt G, Stauss J, Frodl T, Tatsch K et al. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a¹²³I-iodobenzamide SPECT study. J Nucl Med 2005;46:1028–1033PubMed

12.

Brucke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991;11:220–228PubMed

13.

Oertel WH, Tatsch K, Schwarz J, Kraft E, Trenkwalder C, Scherer J, et al. Decrease of D2 receptors indicated by¹²³I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson’s disease. Ann Neurol 1992;32:743–748CrossRefPubMed

14.

Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996;93:9235–9240CrossRefPubMed

15.

Booij J, Korn P, Linszen DH, van Royen EA. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997;24:674–677PubMed

16.

Laruelle M, D’Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997;17:162–174CrossRefPubMed

17.

Guardia J, Catafau AM, Batlle F, Martin JC, Segura L, Gonzalvo B, et al. Striatal dopaminergic D₂ receptor density measured by [¹²³I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry 2000;157:127–129PubMed

18.

Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen AG. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J Nucl Med 1993;34:2076–2084PubMed

19.

Hertel A, Weppner M, Baas H, Schreiner M, Maul FD, Baum RP, et al. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy. Nucl Med Commun 1997;18:811–822PubMedCrossRef

20.

Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using¹²³I-labelled dopamine D₂ receptor ligands. Eur J Nucl Med Mol Imaging 2002;29:BP23–BP29CrossRefPubMed

21.

Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of¹²³I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med 2000;41:220–227PubMed

22.

Popperl G, Radau P, Linke R, Hahn K, Tatsch K. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nucl Med Commun 2005;26:39–43CrossRefPubMed

23.

Verhoeff NP, Brucke T, Podreka I, Bobeldijk M, Angelberger P, Van Royen EA. Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with¹²³I-IBZM using the rotating gamma camera. Nucl Med Commun 1991;12:687–697PubMedCrossRef

24.

Gutzki J, Martin B, Wilke F, Buchert R, Mester J, Clausen M. Time dependence of striatum to background ratio in 123-I-IBZM SPET. Eur J Nucl Med Mol Imaging 2003;30:S157CrossRef

25.

Buchert R, Mester J, Bohuslavizki KH, Clausen M. Performance characteristics of a new low-cost four-headed small-field-of-view gamma camera dedicated for brain imaging. J Nucl Med 2001;42:886

26.

Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995;2:189–210CrossRef

27.

Larisch R, Meyer W, Klimke A, Kehren F, Vosberg H, Muller-Gartner HW. Left-right asymmetry of striatal dopamine D2 receptors. Nucl Med Commun 1998;19:781–787PubMedCrossRef

28.

Duarte P, Hustinx R, Couturier O, Smith RJ, Alavi A. Hottest pixel analysis: useful value or statistical artifact? J Nucl Med 1999;40:292P

29.

Kuikka JT, Bergstrom KA, Ahonen A, Hiltunen J, Haukka J, Lansimies E, et al. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356–360CrossRefPubMed

30.

Berding G, Gratz KF, Kolbe H, Meyer GJ, Dengler R, Knoop BO, et al.¹²³I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia. Nuklearmedizin 1994;33:194–199PubMed

31.

Weissenborn K, Berding G, Kostler H. Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy. Metab Brain Dis 2000;15:173–178CrossRefPubMed

32.

Muller-Vahl KR, Berding G, Kolbe H, Meyer GJ, Hundeshagen H, Dengler R, et al. Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurol Scand 2000;101:165–171CrossRefPubMed

33.

Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–39CrossRefPubMed

34.

Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94–98PubMedCrossRef

35.

Armitage P, Berry G. Statistical methods in medical research, 3rd edn. Malden, USA: Blackwell Science Ltd; 1998

36.

Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–310PubMed

37.

Acton PD, Pilowsky LS, Suckling J, Brammer MJ, Ell PJ. Registration of dynamic dopamine D2 receptor images using principal component analysis. Eur J Nucl Med 1997;24:1405–1412CrossRefPubMed

38.

Nikkinen P, Liewendahl K, Savolainen S, Launes J. Validation of quantitative brain dopamine D2 receptor imaging with a conventional single-head SPET camera. Eur J Nucl Med 1993;20:680–683CrossRefPubMed

39.

Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 1999;9:545–553CrossRefPubMed

40.

Gispert JD, Pascau J, Reig S, Martinez-Lazaro R, Molina V, Garcia-Barreno P, et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage 2003;19:601–612CrossRefPubMed

41.

Van Laere K, Koole M, D’Asseler Y, Versijpt J, Audenaert K, Dumont F, et al. Automated stereotactic standardization of brain SPECT receptor data using single-photon transmission images. J Nucl Med 2001;42:361–375PubMed

42.

Laulumaa V, Kuikka JT, Soininen H, Bergstrom K, Lansimies E, Riekkinen P. Imaging of D2 dopamine receptors of patients with Parkinson’s disease using single photon emission computed tomography and iodobenzamide I 123. Arch Neurol 1993;50:509–512PubMed

43.

Stamatakis EA, Glabus MF, Wyper DJ, Barnes A, Wilson JT. Validation of statistical parametric mapping (SPM) in assessing cerebral lesions: A simulation study. Neuroimage 1999;10:397–407CrossRefPubMed

44.

Jenkins TW, Truex RC. Dissection of the human brain as a method for its fractionation by weight. Anat Rec 1963;147:359–366CrossRefPubMed

45.

Acton PD, Pilowsky LS, Kung HF, Ell PJ. Automatic segmentation of dynamic neuroreceptor single-photon emission tomography images using fuzzy clustering. Eur J Nucl Med 1999;26:581–590CrossRefPubMed

46.

Plotkin M, Amthauer H, Quill S, Marzinzik F, Klostermann F, Klaffke S, et al. Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases. J Neural Transm 2005;112:1355–1361CrossRefPubMed

47.

Parellada E, Lomena F, Catafau AM, Bernardo M, Font M, Fernandez-Egea E, et al. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. Psychiatry Res 2004;130:79–84PubMedCrossRef

48.

Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W.¹²³I-beta-CIT and¹²³I-IBZM-SPECT scanning in levodopa-naive Parkinson’s disease. Mov Disord 1998;13:438–445CrossRefPubMed

49.

Hwang WJ, Yao WJ, Wey SP, Shen LH, Ting G. Downregulation of striatal dopamine D2 receptors in advanced Parkinson’s disease contributes to the development of motor fluctuation. Eur Neurol 2002;47:113–117CrossRefPubMed

Title: IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies
Authors: Ralph Buchert
Georg Berding
Florian Wilke
Brigitte Martin
Daniel von Borczyskowski
Janos Mester
Winfried Brenner
Malte Clausen
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0067-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2006

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone

Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors

Role of 99mTc-sestamibi SPECT in accurate selection of primary hyperparathyroid patients for minimally invasive radio-guided surgery

Instant gratification must wait

[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity

Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification